Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- doxorubicin
- interferon alfa-2b / ribavirin
Interactions between your drugs
DOXOrubicin interferon alfa-2b
Applies to: doxorubicin, interferon alfa-2b / ribavirin
Human lymphoblastoid interferon has been shown to enhance the antitumor activity of doxorubicin and cyclophosphamide in animal models by delaying the G2 cell division phase and increasing the number of cells in the S phase. The clinical significance of this finding is unknown.
References (2)
- Balkwill FR, Mowshowitz S, Seilman SS, et al. (1984) "Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes." Cancer Res, 44, p. 5249-55
- Kang Y, Perry RR (1993) "Modulatory effects of tamoxifen and recombinant human alpha- interferon on doxorubicin resistance." Cancer Res, 53, p. 3040-5
Drug and food interactions
ribavirin food
Applies to: interferon alfa-2b / ribavirin
ADJUST DOSING INTERVAL: Food enhances the oral absorption and bioavailability of ribavirin. Administration of a single oral dose of ribavirin following a high-fat meal delayed absorption (Tmax was doubled) but increased the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by up to 70% compared to administration in the fasting state.
MANAGEMENT: To ensure maximal oral absorption, ribavirin should be administered with or immediately after a meal.
References (2)
- (2003) "Product Information. Copegus (ribavirin)." Roche Laboratories
- (2004) "Product Information. Rebetol (ribavirin)." Schering-Plough Corporation
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.